Boosting eEF2K levels in CD4+ T cells to curtail the proinflammatory microenvironment could potentially usher in a novel approach for the prevention and treatment of inflammatory conditions, such as rheumatoid arthritis, multiple sclerosis, and ulcerative colitis. This evidence concerns the gene CD4 and multiple sclerosis.